Benitec Patent Revoked by EPO; Company Licenses IP from Galapagos | GenomeWeb

NEW YORK (GenomeWeb) – Benitec Biopharma last week announced that the European Patent Office has upheld its previous decision to revoke one of the company's core patents based on opposition filed by biotech firm Galapagos and chemical giant BASF.

Following the EPO's ruling, Benitec said that it has now taken a non-exclusive license to a Galapagos patent covering the use of siRNAs to lower target RNA levels in cells, which it said will give it the freedom to develop its pipeline of expressed RNAi therapeutics in Europe.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.